Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Open-label Study of Intravenous Iron Isomaltoside 1000 (Monofer) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)

Next Previous
Trial Profile

A Phase III, Randomized, Open-label Study of Intravenous Iron Isomaltoside 1000 (Monofer) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ferric derisomaltose (Primary) ; Ferrous sulfate
  • Indications Chemotherapy-induced anaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms PROFOUND
  • Sponsors Pharmacosmos

Most Recent Events

  • 01 Mar 2016 Primary endpoint has been met, (Change in Hb Concentration), according to the results published.
  • 01 Mar 2016 Results published in the Pharmacotherapy.
  • 26 Jul 2014 According to the European Clinical Trials Database record, status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top